CP
TVTX icon

CenterBook Partners’s Travere Therapeutics TVTX Stock Holding History

CenterBook Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
24,818
-132,304
-84% -$5.87M 0.07% 300
2026
Q1 		$4.67M Buy
+157,122
New +$4.7M 0.25% 107

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CenterBook Partners's TVTX Position: Q2 2026 in Review

CenterBook Partners reduced its Travere Therapeutics (TVTX) stake by 84% in Q2 2026, selling an estimated $5.87M and leaving 24,818 shares worth $1.41M. The position accounts for 0.07% of the portfolio, ranked #300.

CenterBook Partners first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.67M in Q1 2026. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • CenterBook Partners held 24,818 shares of Travere Therapeutics worth $1.41M as of Q2 2026.
  • CenterBook Partners sold 132,304 Travere Therapeutics shares in Q2 2026, an estimated $5.87M.
  • Travere Therapeutics made up 0.07% of CenterBook Partners's portfolio in Q2 2026, its #300 holding.
  • CenterBook Partners first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • CenterBook Partners's Travere Therapeutics position peaked at $4.67M in Q1 2026.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.